irinotecan has been researched along with wortmannin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, K; Imai, Y; Ueda, Y; Yamagishi, H; Yoshimori, M | 1 |
| Bae, Y; Frohman, H; Le, AT; Lee, EY; Mark Evers, B; Napier, D; Reichel, D; Roller, N; Rychahou, P; Weiss, HL; Zaytseva, YY | 1 |
2 other study(ies) available for irinotecan and wortmannin
| Article | Year |
|---|---|
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Topotecan; Wortmannin | 2012 |
Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles.
Topics: Animals; Colorectal Neoplasms; Drug Carriers; Gonanes; HT29 Cells; Humans; Irinotecan; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Nanoparticles; Phosphoinositide-3 Kinase Inhibitors; Polymers; Topoisomerase I Inhibitors; Wortmannin | 2018 |